IGFBP-1

Low fasting IGFBP-1 has been associated with future type 2 diabetes, sometimes years before diagnosis. Insulin suppresses production of this protein in the liver, so a low result often accompanies high insulin exposure. But the result also depends on how your liver responds to insulin, how much insulin your pancreas makes, and whether you're fasting or ill.

For assessing diabetes risk or monitoring metabolic health, this is an exploratory marker. There are no established treatment targets, and studies haven't shown that adding it to routine testing improves health outcomes. A higher result can accompany improved metabolism, reduced insulin production, or illness, which prevents a simple higher-is-better interpretation.

How Insulin Changes This Protein

IGFBP-1 is made mainly by the liver and binds IGF-1 and IGF-2. These hormones help regulate growth and metabolism. Binding changes how readily they reach and act on cells; depending on the protein's chemical form and the tissue, it can restrain or support their effects.

Insulin arriving from the pancreas usually reduces the liver's production of IGFBP-1. Levels can fall after eating and rise during fasting. People with obesity often have lower fasting levels, and the liver can retain this response to insulin even when other tissues have become insulin resistant. Insulin deficiency, as in untreated type 1 diabetes, can also raise levels.

Type 2 Diabetes Risk

A Swedish study followed 664 middle-aged adults without diabetes for 17 years. Diabetes or impaired glucose tolerance developed in 12.6% of those in the lowest fifth of baseline IGFBP-1, compared with 1.5% in the highest fifth. Impaired glucose tolerance means blood sugar remains high after a glucose drink. The association with low baseline levels remained after adjustment for age, sex, waist size, and inflammation.

In another cohort of older adults, those above the sex-specific median had about half the diabetes risk of those below it during roughly seven years of follow-up. That association was no longer statistically clear after accounting for body weight and fasting insulin. A separate study in Swedish women also linked low levels and a larger waist to later diabetes. These findings support a connection with insulin metabolism, but they don't establish how much this test adds to existing risk assessment.

The direction isn't consistent in every population. An analysis of 414 adults at high risk of diabetes, drawn from three lifestyle trials, found that higher IGFBP-1 and lower IGF-1 predicted progression to diabetes. The researchers linked this pattern to poorer insulin secretion. A rise can therefore have different explanations, and these studies haven't established a sequence of results that reliably stages diabetes in an individual.

Fatty Liver and Liver Insulin Resistance

Research supports a link between fasting serum IGFBP-1 and the liver's response to insulin. One study measured liver fat in 113 adults without diabetes and directly tested liver insulin sensitivity in 78 participants. Higher IGFBP-1 was associated with greater liver insulin sensitivity and less liver fat, with an association that remained after accounting for body size.

Its correlation with directly measured liver insulin sensitivity was somewhat stronger than the correlations for fasting insulin or C-peptide in that study. Insulin reaching the liver from the pancreas differs from insulin measured in an arm vein because the liver removes some of it. That helps explain the interest in IGFBP-1, but a blood concentration remains an indirect measure. It hasn't been validated to diagnose fatty liver, grade liver damage, or determine an individual treatment plan.

Heart Disease, Stroke, and Survival

In several studies of older adults or people with vascular disease, higher levels were associated with worse outcomes. The populations and comparisons differed, so their results shouldn't be applied directly to a healthy younger adult.

A separate study after heart attack also linked higher levels to long-term mortality, but not to recurrent cardiovascular events. Other work in people with type 2 diabetes linked lower levels to artery disease and hypertension. These are associations in different clinical settings, not evidence that changing IGFBP-1 itself changes cardiovascular risk.

In a study of nearly 5,000 older women, those in the highest quarter of serum levels had about 1.8 times the adjusted odds of low relative muscle mass compared with those in the lowest quarter. Because muscle mass and the protein were assessed together, this doesn't show that the protein caused muscle loss or that it can track muscle loss reliably. Illness, nutritional state, insulin secretion, and kidney function can all complicate the interpretation.

Gestational Diabetes

Pregnancy changes both the amount and sources of IGFBP-1. The placenta and pregnancy-related uterine tissue contribute to its biology, so pregnancy results need a different context from results outside pregnancy.

A study that first examined gene activity in 434 placentas then investigated circulating IGFBP-1 in separate pregnancy cohorts. Lower early-pregnancy plasma levels were associated with greater insulin resistance and later gestational diabetes. The placental tissue findings and the maternal blood findings are distinct measurements. This remains a research use and doesn't replace glucose-based testing for gestational diabetes.

Cancer Research Findings

Studies have reported higher serum IGFBP-1 in people with esophageal, stomach, and colorectal cancers. One upper digestive cancer study included 2,028 participants across its study groups. In its validation cohort, the research assay identified about 72% of early cancers while classifying about 91% of healthy controls as negative.

Those figures came from comparisons involving people with known cancer and selected controls. They don't establish accuracy when screening otherwise healthy people, and the research assay isn't necessarily the assay used for your test. No benefit from IGFBP-1-based cancer screening has been established. An elevated result alone doesn't diagnose cancer or justify a cancer investigation.

When Results Can Be Misleading

Most metabolic studies measure IGFBP-1 in serum or plasma obtained from blood draws. This test's catalog specifies blood but doesn't identify the blood fraction or measurement method. Published concentrations and research cutpoints therefore can't be assumed to apply directly to your report.

• Food and fasting change the result. Levels can fall within hours of eating and rise substantially during prolonged fasting; a higher result after a longer fast doesn't establish better insulin sensitivity.
• Prolonged strenuous exercise can cause a large temporary increase. One endurance study found an increase of up to 12-fold without carbohydrate feeding, which is different from a sustained change in resting metabolism.
• Severe illness and recent major medical events can alter levels. Studies after heart attack and during prolonged critical illness show why a result in these settings needs a different interpretation.
• Medicines can affect the result in different directions. In a small human study, dexamethasone lowered serum IGFBP-1. Results from cells exposed to steroids don't reliably predict the direction in your blood.
• Reduced kidney function can be associated with higher circulating levels, so an unexplained elevation isn't automatically evidence of good insulin sensitivity.
• Age, sex, and pregnancy affect interpretation. Different assays also detect chemically modified forms of the protein differently, which can make results across methods or laboratories difficult to compare.

What a Trend Can Show

Repeated results collected under comparable conditions can describe a change in your circulating IGFBP-1. They haven't been validated as a score of liver recovery or diabetes prevention, and there is no established change that reliably means your risk has improved. Your own baseline doesn't become a treatment target because population cutpoints are uncertain.

The accompanying glucose and insulin results matter. Rising IGFBP-1 with improving glucose control can have a different explanation from rising IGFBP-1 with worsening blood sugar. Symptoms, weight changes, medicines, and kidney function can help distinguish those situations.